Cabozanix (cabozantinib) is a pan-tyrosine kinase inhibitor.
Cabozanix (cabozantinib) is a pan-tyrosine kinase inhibitor. These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment.
Cabozanix is specifically approved for the treatment of progressive, metastatic medullary thyroid cancer.
Cabozanix is supplied as a capsule for oral administration. The recommended daily dose of Cabozanix is 140 mg (one 80-mg and three 20-mg capsules). Cabozanix should not be administered with food. Patients should not to eat for at least 2 hours before and at least 1 hour after taking Cabozanix. Continue treatment until disease progression or unacceptable toxicity occurs.
Cabozanix is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC).
Beacon Introduces Global Patient Support Program
Life saving drugs are either beyond the reach of general people or not available in many countries. Because of the patient exemptions for Bangladeshi companies,Beacon Pharmaceuticals can manufacture the patented drugs. As a support to global patient…Read More
Registered & Licensed by Regulatory
Authority of Bangladesh
Cabozanix (Cabozantinib) is a registered product by the Directorate General of Drug Administration & Licensing Authority (Drugs) of Bangladesh. Drug Registration Number: 000-000-000 Inclusion Date: 00-00-0000 Valid up to: 00-00-0000
HEAD OFFICE
Beacon Pharmaceuticals PLC
9/B/2,Toyenbee Circular Road,
Motijheel,Dhaka-1223, Bangladesh.
Phone: +880-2-57165371-79
E-mail: info@beaconpharma.com.bd
Web: beaconpharma.com.bd
GLOBAL MARKETING PARTNER
Beacon Medicare Limited
9/B/2,Toyenbee Circular Road,
Motijheel,Dhaka-1223, Bangladesh.
Phone: +880-2-57165371-79
E-mail: info@beaconmedicare.com.bd
Web: beaconmedicare.com.bd
